Registration Strip Icon for monitor Customisable watchlists with full streaming quotes from leading exchanges, such as LSE, NASDAQ, NYSE, AMEX, Bovespa, BIT and more.

Marker Therapeutics (MRKR)

Marker Therapeutics Inc
Date:
Sort by:
 Showing the most relevant articles for your search:NASDAQ:MRKR
DateTimeSourceHeadlineSymbolCompany
28/08/202413:00GlobeNewswire Inc.Korro Announces Addition of Industry Veteran Katharine Knobil to and Resignation of David Lucchino From Its Board of DirectorsNASDAQ:MRKRMarker Therapeutics Inc
14/08/202421:47Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:MRKRMarker Therapeutics Inc
14/08/202421:39Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:MRKRMarker Therapeutics Inc
14/08/202421:30GlobeNewswire Inc.Marker Therapeutics Reports Second Quarter 2024 Financial Results and Provides Business UpdatesNASDAQ:MRKRMarker Therapeutics Inc
12/08/202412:12Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:MRKRMarker Therapeutics Inc
12/08/202412:00GlobeNewswire Inc.Marker Therapeutics Awarded $2 Million Grant from NIH in Support of Phase 1 Study Investigating MT-601 in CAR-Relapsed Patients with Non-Hodgkin’s LymphomaNASDAQ:MRKRMarker Therapeutics Inc
12/06/202421:05Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:MRKRMarker Therapeutics Inc
17/05/202423:25Edgar (US Regulatory)Form SC 13D/A - General statement of acquisition of beneficial ownership: [Amend]NASDAQ:MRKRMarker Therapeutics Inc
15/05/202421:40Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:MRKRMarker Therapeutics Inc
15/05/202421:03Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:MRKRMarker Therapeutics Inc
08/04/202412:00GlobeNewswire Inc.Principal Investigator from City of Hope National Medical Center Invited to Present Clinical Data from Marker Therapeutics APOLLO Study at 11th Global Summit on Hematologic Malignancies NASDAQ:MRKRMarker Therapeutics Inc
25/03/202421:45GlobeNewswire Inc.Marker Therapeutics Reports Year-End 2023 Corporate and Financial ResultsNASDAQ:MRKRMarker Therapeutics Inc
22/03/202416:30GlobeNewswire Inc.Marker Therapeutics to Present at the H.C. Wainwright 2nd Annual Cell Therapy Virtual ConferenceNASDAQ:MRKRMarker Therapeutics Inc
01/03/202413:02Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:MRKRMarker Therapeutics Inc
26/02/202412:58Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:MRKRMarker Therapeutics Inc
22/01/202412:30GlobeNewswire Inc.Marker Therapeutics Receives Approval from United States Adopted Name (USAN) Council and International Nonproprietary Names (INN) Expert Committee for “Neldaleucel” as Nonproprietary Name for MT-601NASDAQ:MRKRMarker Therapeutics Inc
08/01/202413:30Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:MRKRMarker Therapeutics Inc
08/01/202413:24GlobeNewswire Inc.Marker Therapeutics Announces Clinical Program Updates and Pipeline PrioritizationNASDAQ:MRKRMarker Therapeutics Inc
21/12/202316:00GlobeNewswire Inc.Marker Therapeutics Announces Participation in Biotech Showcase and the 19th Annual Non-Dilutive Funding Summit During “J.P. Morgan Week 2024”NASDAQ:MRKRMarker Therapeutics Inc
11/12/202312:35Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:MRKRMarker Therapeutics Inc
11/12/202312:00GlobeNewswire Inc.Marker Therapeutics Announces Sustained Complete Response in First Lymphoma Patient Treated with MT-601 following CAR T RelapseNASDAQ:MRKRMarker Therapeutics Inc
20/11/202321:37Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:MRKRMarker Therapeutics Inc
09/11/202322:03Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:MRKRMarker Therapeutics Inc
09/11/202322:00GlobeNewswire Inc.Marker Therapeutics Reports Third Quarter 2023 Financial Results and Provides Business UpdatesNASDAQ:MRKRMarker Therapeutics Inc
09/11/202321:31Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:MRKRMarker Therapeutics Inc
11/09/202312:10Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:MRKRMarker Therapeutics Inc
11/09/202312:00GlobeNewswire Inc.Marker Therapeutics Announces Complete Response in First Lymphoma Patient Treated with MT-601 after CAR T RelapseNASDAQ:MRKRMarker Therapeutics Inc
30/08/202313:00GlobeNewswire Inc.Marker Therapeutics to Present at the H.C. Wainwright 25th Annual Global Investment ConferenceNASDAQ:MRKRMarker Therapeutics Inc
14/08/202321:37Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:MRKRMarker Therapeutics Inc
14/08/202321:30GlobeNewswire Inc.Marker Therapeutics Reports Second Quarter 2023 Financial Results and Provides Business UpdateNASDAQ:MRKRMarker Therapeutics Inc
 Showing the most relevant articles for your search:NASDAQ:MRKR

Your Recent History

Delayed Upgrade Clock